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Abstract
Objective: Intestinal autoimmunity with gastrointestinal (GI) dysfunction has been shown 
in patients with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy 
(APECED). Patients lack entero-endocrine (EE) cells and have circulating autoantibodies 
(Aabs) against critical enzymes in serotonin (5-HT) biosynthesis.
Design: We sought to determine the serum levels of 5-HT, tryptophan (Trp) metabolites 
and L-DOPA in 37 Finnish APECED patients and to correlate their abundance with the 
presence of TPH and AADC Aabs, GI dysfunction and depressive symptoms. We also 
performed an exploratory analysis of the gut microbiome.
Methods: Serum 5-HT, L-DOPA and Trp metabolite levels were determined by liquid 
chromatography-electrospray ionization-tandem mass spectrometry (LC-ESI-MS/MS).  
TPH and AADC Aabs were measured by ELISA. Depression was assessed with a 
structured RBDI questionnaire. The V3–V4 regions of the bacterial 16S rRNA gene were 
sequenced for gut microbiome exploration.
Results: Serum 5-HT levels were significantly decreased (130 ± 131 nmol/L vs 
686 ± 233 nmol/L, P < 0.0001) in APECED patients with TPH-1 (±AADC) Aabs compared 
to controls and patients with only AADC Aabs. Reduced 5-HT levels correlated with 
constipation. The genus Escherichia/Shigella was overrepresented in the intestinal 
microbiome. No correlation between serum Trp, 5-HT or l-DOPA levels and the RBDI 
total score, fatigue or sleep disorders was found.
Conclusions: This exploratory study found low serum levels of 5-HT to be associated 
with constipation and the presence of TPH-1 and AADC Aabs, but not with symptoms of 
depression. Hence, serum 5-HT, TPH1 and AADC Aabs should be determined in APECED 
patients presenting with GI symptoms.
Introduction
Autoimmune polyendocrinopathy-candidiasis-
ectodermal dystrophy (APECED, OMIM 240300) or 
autoimmune polyendocrine syndrome type 1 (APS-1) 
is a rare autosomal recessive disease caused by a loss-of-
function mutation of the AIRE (Autoimmune Regulator) 
gene located on chromosome 21 (21q22.3) (1, 2, 3, 4). 
The disease predisposes to chronic mucocutaneous 
candidiasis and various autoimmune disorders that impair 
quality of life (1). AIRE is normally expressed in thymus, 
where it is responsible for the elimination of potentially 
autoreactive cytotoxic T-cells, which in APECED will 
destroy target cells. Due to the loss of AIRE function, 
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APECED patients also have a lack of regulatory T-cells 
and, thus, APECED is characterized by a variety of high-
titer circulating autoantibodies (Aabs). Organ- specific 
antibodies in APECED do not cause tissue destruction per 
se, but rather indicate the destructive action of cytotoxic 
T-cells. The most common non-organ-specific Aabs are 
neutralizing Aabs against type I interferon (IFN-α and 
-ω) and Th17 cytokines (IL-17A, IL-17F, IL-22). Patients 
also display Aabs directed against intracellular enzymes 
involved in hormone and neurotransmitter biosynthesis 
(5, 6). Among the latter, Aabs directed against aromatic 
l-amino acid decarboxylase (or DOPA decarboxylase, 
AADC) and tryptophan hydroxylase (TPH) are commonly 
found in APECED patients (7, 8, 9) and their presence 
has been associated with the lack of entero-endocrine 
(EE) cells of the gastrointestinal (GI) tract (9, 10). 
Serotonin (5-hydroxytryptamine, 5-HT) is synthesized 
mainly (95%) by GI EE cells and in smaller amounts in 
the central nervous system (11). Its synthesis is derived 
from tryptophan (Trp) in a two-step reaction, involving 
TPH-1 or TPH-2 and AADC. AADC catalyzes both the 
decarboxylation of 5-hydroxytryptophan to 5-HT and 
the conversion of l-DOPA to dopamine in the brain. 5-HT 
is an important biogenic amine and neurotransmitter 
that affects intestinal motility as well as mood, sleep and 
appetite (11). APECED patients with circulating TPH-1 
Aabs have been shown to have significantly lower serum 
levels of 5-HT than patients without such Aabs (12). 
We have previously reported that severe constipation 
significantly correlated with TPH-1 and/or AADC Aabs 
and with lacking 5-HT expression in GI EE cells (9). Both 
5-HT and dopamine are known to be related to the mental 
balance of an individual, and it is of interest to note that 
we have found depressive symptoms in 29% of Finnish 
APECED patients (13).
Besides, alteration of gut microbiome composition has 
been shown to be associated with various diseases such as 
mental depression and autoimmune diseases (14). It has 
become evident that gut microbes may directly influence 
the central nervous system function by controlling the 
production of neurotransmitters, such as 5-HT in the gut 
(15).
In the present study, we assessed the serum levels 
of 5-HT, L-DOPA and Trp metabolites in our cohort of 
Finnish APECED patients and compared the results 
with the presence of TPH-1, TPH-2 and AADC Aabs and 
with clinical manifestations such as GI dysfunction 
and depressive symptoms. We also compared the gut 
microbiota of APECED patients against that of healthy 
control persons to assess whether there were any 
indications of potential microbiome differences between 
the two populations.
Materials and methods
Design and patients
We recruited 37 Finnish APECED patients with confirmed 
AIRE mutations (25 women and 12 men, sex ratio 2.1:1). 
As the Finnish patient group has a history of willingly 
participating in research of their disease, the study 
recruitment and contact information was collected with 
the help of the APECED patient’s association (APECED 
ja Addison Ry, http://www.apeced.org). Most of these 
patients have been included in various publications on 
APECED in Finland (1, 13), including our previous work 
about gastrointestinal autoimmunity (9). The mean age 
of the cohort was 39.9 years (range 9–70 years), including 
five children aged between 9 and 16 years with a mean 
age of 12.4 years. The study was approved by the Ethics 
Committee of Medicine, Helsinki and Uusimaa Joint 
Authority (HUS 1127/2016). Each participant (or their 
parents if under the age of 18 years) signed an informed 
consent and permission to review all their hospital records. 
For serum metabolite analysis, an additional 12 healthy, 
age- and sex-matched volunteers (control persons) 
participated, after a 24-hour long serotonin-free diet (see 
below). The control group had no features of APECED or 
any other autoimmune disease, no GI symptoms, and 
nobody was on an antidepressant medication.
Questionnaire
The Raitasalo’s modification of the Beck Depression 
Inventory (RBDI) mood questionnaire is a self-reported 
questionnaire that has been used in Finland for the 
past 30 years for screening and grading depression. This 
modified Finnish version of Beck’s 13-item depression 
scale has 13 questions for depression. Depression is 
measured on the basis of 13 items scoring from 0 to 3, 
and score ranges from zero to 39 points. Five to seven 
points refer to mild depression, 8 to 15 points to moderate 
depression and over 16 points to severe depression. We 
also included two questions regarding gastrointestinal 
function, that is, current chronic constipation or diarrhea 
(without any known cause) or both.
The questionnaire was sent to all 37 patients. Twenty-
six patients completed and returned the questionnaires 
(response rate 70.3%). One questionnaire was anonymous 
and one patient answered only the GI-related questions.
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Assay of autoantibodies
Serum circulating Aabs against recombinant AADC 
(Biosite, Täby, Sweden), TPH-1 (Sino Biological Inc., 
Beijing, China) and TPH-2 (OriGene Technologies Inc. 
Rockville, MD, USA) were assayed with a validated 
in-house ELISA as previously described in detail (9). Sera 
from healthy blood donors obtained from the Finnish Red 
Cross blood service served as reference. The cut-off value 
was set as mean ± 2 s.d. of the reference samples.
Serum levels of 5-HT, L-DOPA and Trp metabolites
Of the 37 patients, 26 patients (16 women and 10 men, 
participation rate 70.2%) and 12 healthy, age- and sex-
matched volunteers participated in the measurement of 
serum metabolite levels. The sera were drawn after an 
overnight fasting and a 24-hour long serotonin-free diet, 
refraining patients and controls from eating anything 
that might include serotonin or its precursor such as nuts, 
banana, avocado, plum, kiwi, pineapple, grape, melons, 
date, tomato, eggplant and blue cheese. The venous blood 
specimens (5 mL) were collected in plastic anticoagulant 
gel-free vacuum tubes, sent at room temperature to our 
laboratory, where serum was separated by centrifugation 
and stored at −80°C. For the determination of 5-HT, 
L-DOPA and various Trp metabolites by liquid 
chromatography-electrospray ionization-tandem mass 
spectrometry (LC-ESI-MS/MS), the frozen serum samples 
were sent on dry ice to the Institute of Functional 
Genomics in Regensburg, Germany. LC-ESI-MS/MS 
analysis was performed as previously described (16) with 
the inclusion of l-DOPA. The latter elutes at 2.55 min and 
the transitions m/z 198.2 ⟶ m/z 152 for L-DOPA and 
m/z 201.2 ⟶ m/z 155 for the corresponding deuterated 
internal standard L-DOPA-d3 were monitored. Other 
metabolites determined included Trp and its metabolites 
3-hydroxykynurenine (HK), nicotinamide (NAM), 5-HT, 
kynurenine (KYN), xanthurenic acid, kynurenic acid (KA), 
anthranilic acid (AA), 3-hydroxyanthranilic acid (HAA), 
5-hydroxyindole-3-acetic acid (HIAA), indole-3-lactic acid 
(ILA), indole-3-acetic acid (IAA) and indole-3-propionic 
acid (IPA).
Gut microbiome
Stool specimens for 16S rRNA-based gut microbiome 
composition analysis were collected by ten Finnish 
APECED patients (aged 17–58, seven females) and eight 
healthy Finnish volunteers (aged 16–77, 5 females) at 
home using collection kits preloaded with DNA stabilizer 
(PSP Spin Stool DNA Plus Kit: Stratec Molecular GmbH, 
Berlin, Germany). The tubes were then kept in the 
subject’s home freezer until the clinical visit, after which 
they were stored at −80°C. DNA extraction was performed 
with the QIAamp Fast DNA Stool Mini Kit, Cat No. 51604 
(Qiagen), according to the manufacturer’s instructions. 
PCR amplification (two-step), quantification, pooling, 
purification and pool quality assessment of the bacterial 
16S rRNA gene were performed according to a previously 
published protocol (17), except that in the present 
study, we amplified the V3–V4 regions. One PCR blank 
(no template) was also sequenced to assess potential 
contamination. For amplification of these regions, we 
used a mixture of the ‘universal’ bacterial primers 341F1-4 
(5′ CCTACGGGNGGCWGCAG 3′) and 785R1-4 (5′ 
GACTACHVGGGTATCTAATCC 3′), with the following 
partial Illumina TruSeq adapter sequences added to their 
5′ ends:
F1: ATCTACACTCTTTCCCTACACGACGCTCTTCCGATCT,
F2: ATCTACACTCTTTCCCTACACGACGCTCTTCCGA 
TCTgt,
F3: ATCTACACTCTTTCCCTACACGACGCTCTTCCGATC 
Tagag,
F4: ATCTACACTCTTTCCCTACACGACGCTCTTCCGATC 
Ttagtgt,
R1: GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT,
R2: GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTa,
R3: GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTtct,
R4: GTGACTGGAGTTCAGACGTGTGCTCTTCCGATC 
Tctgagtg.
The small letters correspond to additional nucleotides 
that are added for mixing purposes during sequencing. 
The amplicon sequencing was performed with an 
Illumina MiSeq (v3 600 cycle kit), with 325 bases for the 
forward and 285 bases for the reverse read. DNA library 
creation and sequencing were performed at the DNA 
Sequencing and Genomics Laboratory of the University 
of Helsinki, Finland. The raw sequencing data amounted 
to 3,733,753 sequences. FastQC (18) and cutadapt (19) 
were used to assess the sequence quality and to trim 
primers, respectively. The sequence data were then 
clustered into Operational Taxonomic Units (OTUs) and 
classified taxonomically with mother (20) following the 
Standard Operating Procedure for MiSeq available online 
(http://www.mothur.org/wiki/MiSeq_SOP). The final data 
set (after removal of the PCR blank) consisted of a total 
of 2,778,416 sequence reads representing 3,662 OTUs. 
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The largest amount of reads per sample was 153,653, 
and the lowest 85,508, with a mean of 120,801 reads per 
sample.
Statistical analysis
Statistical analysis was conducted with SPSS Statistics 
22 (SPSS Inc., an IBM company). Quantitative data were 
expressed as mean values ± s.d. Comparisons of categorical 
variables were performed using the chi-square test. 
Serum metabolite levels between APECED patients and 
controls were compared by ANOVA with Tukey’s and 
Dunnett’s post hoc test. Correlation between RBDI scores 
and serum metabolite levels were analyzed by Spearman’s 
rank correlation coefficient. A P value of <0.05 was 
considered significant. All sequence data were imported 
into R (https://www.R-project.org/) and manipulated 
with the phyloseq package (21). Differential abundance 
of bacterial taxa was analyzed using DESeq2 (22), which is 
based on negative binomial linear models. Alpha diversity 
was analyzed with non-rarefied OTU-level data using the 
Shannon and inverse Simpson indices. Statistical tests were 
performed with the (unpaired) pairwise Wilcoxon rank-
sum test for comparisons between controls and APECED 
subjects. Beta diversity analyses used rarefied data at 
OTU-level, by performing Non-Metric Multidimensional 
Scaling (NMDS) on Bray–Curtis dissimilarity, as well as 
Permutational Multivariate Analysis of Variance Using 
Distance Matrices (adonis, from the vegan package 
(https://cran.r-project.org/web/packages/vegan/index.
html)), an implementation of PERMANOVA. A double-
tailed P value of <0.05 was considered statistically 
significant for all microbiome-related analyses.
Results
Altered 5-HT serum levels associate with 
autoantibodies against TPH-1 and AADC
Circulating Aabs against AADC and TPH-1 were detected 
in 20 (54%) and 15 (40.5%) of the 37 APECED patients, 
respectively. Among the 26 patients for whom Trp 
metabolites analysis was performed, the distribution of 
Aabs was similar: 54% (n = 14) had AADC Aabs and 46% 
(n = 12) had TPH-1 Aabs. None of the APECED patients had 
detectable Aabs against the brain TPH isoenzyme TPH-2. 
The mean (±s.d.) serum 5-HT level was significantly 
decreased in APECED patients with TPH-1 (±AADC) 
Aabs (130 ± 131 nmol/L) compared to healthy controls 
and patients without Aabs or with only AADC Aabs 
(686 ± 233 nmol/L). Although patients with both TPH-1 
and AADC Aabs tended to have lower 5-HT serum levels 
(105 ± 78 nmol/L) than patients with TPH-1 Aabs only 
(217 ± 214 nmol/L), the difference was not statistically 
significant (Fig.  1, Table  1; Supplementary Table 1, see 
section on supplementary data given at the end of this 
article). The sole presence of circulating AADC Aabs did 
not affect 5-HT serum levels compared with controls and 
APECED patients without Aabs. TPH-1 Aabs and/or AADC 
Aabs did not associate with changes in serum levels of Trp 
or any of its metabolites other than 5-HT. Interestingly, 
patients with AADC Aabs alone or in association with 
TPH-1 Aabs had significantly higher serum levels of 
L-DOPA than controls (Table 1).
Constipation symptoms correlate with lower 5-HT 
levels in APECED patients
Four patients (16%, 4/25) reported current and chronic 
diarrhea (1 male, 3 female), three (15.3%, 3/25) 
reported chronic constipation (1 male, 2 female), while 
no one reported both symptoms to be simultaneous/
alternating at the time of the blood sampling. Mean 
5-HT concentration was lower among patients reporting 
constipation compared to those without (24 ± 12 nmol/L 
vs 488 ± 333 nmol/L; P = 0.027) (Fig.  2). No significant 
association with any other metabolite was found. Diarrhea 
did not associate with any metabolite level variation.
Figure 1
Serum serotonin levels (nmol/L) in relation to circulating TPH-1 and AADC 
Aabs. The line represents the mean value of serum serotonin for each 
patient group and healthy control persons.
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Symptoms of depression do not correlate with low 
5-HT serum levels in APECED patients
The complete RBDI questionnaires of 24 (65%) APECED 
patients (18 women; mean age 43 years) yielded a mean 
total RBDI score of 3.4 (range 0–10). Nine patients scored 
>5 – 5 had mild depression (20.8%, score 5–7), while 
four patients suffered from moderate depression (16.6%, 
score 8–15). None had severe depressive symptoms (score 
>15). Three patients reported taking oral anti-depressive 
treatment on a regular basis but their RBDI mean score 
did not differ from that of patients not on anti-depressive 
medication. The highest scores were obtained for the 
questions regarding sleeping disturbances (mean score 
0.96, range 0–3) and fatigue and exhaustion (mean score 
0.64, range 0–3). Ten patients (42%) reported sleeping 
disturbances, 13 (54%) suffered from fatigue, and 
15 (60%) reported having problems with at least one 
of either. Neither RBDI total score nor fatigue nor sleep 
disorder score were correlated to metabolite serum levels 
(Spearman rho P > 0.05, data not shown). The use of 
antidepressants by three patients at the time of sampling 
had no significant impact on the metabolite levels.
Members of the Escherichia/Shigella genus correlate 
with APECED status
Alpha diversity analyses did not produce statistically 
significant results for either inverse Simpson or Shannon 
diversity indices when comparing controls to APECED 
subjects (inverse Simpson P value = 0.21, Shannon P 
value = 0.29; Fig.  3). Beta diversity analysis with NMDS 
using a Bray–Curtis dissimilarity matrix did not show any 
indication of differences between healthy control persons 
and APECED cases (data not shown). Using the Bray–Curtis 
dissimilarity matrix with the adonis implementation of 
PERMANOVA produced a P value of 0.22. These last two 
approaches together suggest that there are no meaningful 
microbial differences between the two groups at the beta 
diversity level.
The DNA amplicon sequencing of the V3–V4 regions 
of the 16S rRNA bacterial gene produced 3662 OTUs 
distributed into 232 genera, 91 families, 46 orders, 27 
classes and 14 phyla. The five most abundant genera 
in the data set, in decreasing order, are Bacteroides, 
Prevotella, Alistipes, Ruminococcus and Roseburia (Fig.  4). 
The five most abundant families are Bacteroidaceae, 
Ruminococcaceae, Lachnospiraceae, Prevotellaceae and 
Porphyromonadaceae. The most abundant phyla are 
Bacteroidetes, Firmicutes, Proteobacteria, Actinobacteria 
Table 1 Serum levels (nmol/L) of Trp metabolites and L-DOPA in APS-1 according to TPH-1 and AADC Aabs.
TPH1− AADC− n = 8 TPH1+ AADC− n = 3 TPH1− AADC+ n = 5 TPH1+ AADC+ n = 7 Controls n = 12e ANOVA
Trp 53,527 ± 8439 56,339 ± 6241 58,618 ± 9356 54,677 ± 9958 58,422 ± 7036 P = 0.68
5-HT 679 ± 339 217 ± 214a 686 ± 59 105 ± 78b 689 ± 210 P < 0.0001
HIAA 63 ± 25 45 ± 34 69 ± 17 51 ± 46 35 ± 16 P = 0.13
AA 11 ± 7 19 ± 10 12 ± 5 15 ± 6 17 ± 7 P = 0.25
HAA 30 ± 6 37 ± 17 32 ± 11 35 ± 17 37 ± 9 P = 0.70
L-DOPA 12 ± 2 12 ± 4 14 ± 4c 16 ± 4d 9 ± 3 P = 0.002
KYN 1157 ± 140 1354 ± 732 1498 ± 335 1459 ± 580 1275 ± 208 P = 0.44
HK 28 ± 9 48 ± 39 41 ± 31 42 ± 21 34 ± 8 P = 0.45
KA 60 ± 032 58 ± 29 54 ± 20 80 ± 77 69 ± 20 P = 0.81
IAA 1242 ± 316 2019 ± 1570 1870 ± 1001 1484 ± 407 1587 ± 429 P = 0.35
NAM 149 ± 80 104 ± 56 182 ± 148 128 ± 54 135 ± 69 P = 0.72
P values for the Dunnett post hoc test comparing patient groups to the control group: a0.0085, bP < 0.0001, c0.026, d0.001. eL-DOPA: only 11 controls.
Figure 2
Serum metabolite concentrations (nmol/L) according to the presence of 
severe constipation.
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and Verrucomicrobia. Differential abundance analysis 
between control persons and APECED subjects was 
performed at OTU and genus levels, adjusting during 
modeling for the presence/absence of constipation 
and diarrhea. Two statistically significant results were 
produced at both the OTU and the genus level (Table 2) 
for comparisons between control and APECED subjects. 
The Enterobacteriaceae OTtu0038 is most probably a false 
positive, given the sensitivity to the presence of a clear 
outlier and its overall low mean abundance. It also shows 
a negative correlation with APECED status. Haemophilus 
could represent a true positive, but this result should be 
taken with skepticism given the very low mean abundance 
of this taxon. Finally, Escherichia/Shigella was detected 
both at the OTU and genus levels (Fig. 5), with the results 
being robust and showing an overrepresentation of this 
taxon in the APECED group. Given the very small number 
of subjects with constipation (4) and/or diarrhea (7), we 
did not pursue investigation into possible associations 
between the latter and taxon abundances, to avoid 
reporting spurious results.
Discussion
GI involvement is one of the numerous manifestations 
of APECED (23). The patients frequently suffer from 
intermitting periods of diarrhea and severe constipation. 
Figure 3
Stool microbiome alpha diversity indices for 
control persons and APECED subjects. Based on 
non-rarefied count data at the OTU level.
Shannon InvSimpson
Control
APECED
Control
APECED
10
20
2.5
3.0
3.5
4.0
Group
Al
ph
a 
Di
ve
rs
ity
 M
ea
su
re
Figure 4
Taxon relative abundances (%) of the control and 
APECED groups. The 20 most common genera in 
the entire data set are explicitly shown.
0
25
50
75
100
Control APECED
M
ea
n 
re
la
tiv
e
 a
bu
n
da
nc
e 
(%
) Genus
Bacteroides
Prevotella
Alistipes
Ruminococcus
Roseburia
Faecalibacterium
Escherichia/Shigella
Parabacteroides
Gemmiger
Dialister
Blautia
Barnesiella
Clostridium_XlVa
Clostridium_XVIII
Bifidobacterium
Akkermansia
Ruminococcus2
Clostridium_IV
Lactobacillus
other taxa
unclassified taxa
This work is licensed under a Creative Commons 
Attribution-NonCommercial 4.0 International License.https://doi.org/10.1530/EC-18-0513
https://ec.bioscientifica.com © 2019 The authors
Published by Bioscientifica Ltd
Downloaded from Bioscientifica.com at 03/26/2019 06:45:37AM
via University of Regensburg
E Naskali et al. Tryptophan metabolite levels 
and gut microbiome in APECED
758:1
These symptoms may reflect serum calcium level 
variation, intestinal infection or autoimmunity (23). 
Malabsorption affects up to 25% of the European patients 
with APECED (23), and up to 80% in an American cohort 
(2). It has been shown that patients with APECED 
typically have a lack of EE cells in the GI tract, which is 
associated with a lack of expression of chromogranin A 
and 5-HT (9, 10, 12). We previously observed that severe 
constipation symptoms were associated with the lack 
of 5-HT expression in the intestinal tract (9) and Scarpa 
and coworkers reported that 5-HT serum levels were 
significantly lower in APECED patients with anti-TPH 
Aabs and GI dysfunction (12).
This study shows that serum 5-HT levels tend to be 
significantly lower in APECED patients (12) and that 
constipation significantly associates with such low 
levels. We also confirm that TPH-1 Aabs associate with 
a decrease in serum 5-HT levels in APECED patients. 
Interestingly, the presence of AADC Aabs alone did not 
associate with lowered 5-HT levels, but the presence of 
both TPH-1 and AADC antibodies seemed to result in 
even lower 5-HT levels. Also, elevated L-DOPA levels 
correlated with AADC antibodies. Since AADC catalyzes 
the conversion of L-DOPA to dopamine, this finding 
might suggest a functional activity of the AADC Aabs. In 
our previous study, we found that AADC Aabs associated 
with constipation (9). However, the present study did not 
include all patients from the previous cohort. As a result, 
the small number of patients reporting constipation and 
diarrhea at the time of blood sampling prevented us to 
perform statistical comparisons between the various 
profiles of circulating autoantibodies, symptoms and 
metabolite levels within the APECED patient group alone.Ta
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Figure 5
Relative abundances (%) of the genus Escherichia/Shigella for control 
persons and APECED subjects.
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We explored also whether the low serum levels of 5-HT 
or any other Trp metabolite levels would be associated with 
symptoms of depression but no such correlation with the 
RBDI score was found. One may discuss whether the cross-
sectional metabolite level determination would reflect 
constant levels and whether the evaluation of depression 
symptoms with one modified BDI questionnaire, the 
RBDI, would have needed an evaluation of cognitive 
function or broad neuropsychological performances.
Nutrients and GI microbiota have an impact on 5-HT 
metabolism. Spore-forming bacteria, Clostridium spp 
especially, produce short-chain fatty acids and tryptamine 
by decarboxylation of tryptophan, which influence 
TPH-1 expression, 5-HT synthesis and/or 5-HT release 
(11, 24). In turn, it is not known whether 5-HT released 
into the intestinal lumen exerts any direct impact on 
gut microbiota composition (11, 25). Indeed, as we have 
reported earlier, APECED patients may also develop Aabs 
against enteric defensins and often lack Paneth cells (26). 
Besides, APECED patients also have Aabs against other 
intestinal cell targets like Villin and AIE-75 (9), which are 
typically found in IPEX autoimmune enteropathy (27).
The results of the present small-scale exploratory 
study on possible connections between the gut microbiota 
and APECED, suggest that either the genus Escherichia or 
Shigella, as well as Haemophilus, may be overrepresented 
in APECED. Sequencing a small section of the 16S rRNA 
gene does not permit to reliably distinguish between 
Escherichia and Shigella, which in any case is a taxonomic 
distinction with little biological and evolutionary validity, 
although of obvious clinical interest. However, given that 
virtually all sequences in this study that were classified 
as Escherichia/Shigella belong to the same OTU detected 
during OTU-level analysis (OTU0006), this OTU probably 
represents E. coli. Regarding alpha diversity, it should be 
noticed that, although statistical significance was not 
reached, the effect estimate is highly suggestive of a drop 
in the microbial diversity in the APECED population 
when compared to controls. It is possible that the lack of 
statistical significance is a false-negative result produced 
by the small sample size, and therefore, lack of statistical 
power. The putative lower diversity in the APECED disease 
state is in agreement with results from previous studies 
of microbiome and disease, which tend to show lower 
alpha diversity estimations for disease states in general. 
All these results should, nevertheless, be regarded as 
tentative, given the aforementioned small sample size of 
the microbiome part of this study, and need validation in 
the form of future studies. The small number of patients 
and controls constitutes a significant limitation of the 
present study, and therefore, it can be considered only 
exploratory in nature. This holds particularly true for the 
microbiome analysis.
In conclusion, we observed very low levels of 
circulating 5-HT in APECED patients to be associated with 
constipation, but not with mental symptoms. Hence, it 
is recommended to determine serum serotonin as well 
as TPH1 and AADC Aabs in APECED patients presenting 
with GI symptoms. Since this study included only Finnish 
APECED patients with a common AIRE mutation, our 
observations need to be confirmed in a larger international 
setting.
Supplementary data
This is linked to the online version of the paper at https://doi.org/10.1530/
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